Ownership Capital B.V. Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

Ownership Capital B.V. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 771,618 shares of the company’s stock after selling 37,666 shares during the period. Zoetis makes up approximately 4.8% of Ownership Capital B.V.’s investment portfolio, making the stock its 10th biggest position. Ownership Capital B.V. owned about 0.17% of Zoetis worth $150,759,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ZTS. Mesirow Financial Investment Management Inc. lifted its position in Zoetis by 105.5% during the third quarter. Mesirow Financial Investment Management Inc. now owns 82,298 shares of the company’s stock worth $16,080,000 after purchasing an additional 42,258 shares during the period. Atria Investments Inc lifted its stake in Zoetis by 1.7% during the third quarter. Atria Investments Inc now owns 91,868 shares of the company’s stock worth $17,949,000 after purchasing an additional 1,495 shares during the last quarter. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at $33,000. TCTC Holdings LLC increased its stake in shares of Zoetis by 2.8% in the 3rd quarter. TCTC Holdings LLC now owns 41,760 shares of the company’s stock valued at $8,159,000 after purchasing an additional 1,153 shares during the last quarter. Finally, Bridges Investment Management Inc. raised its holdings in shares of Zoetis by 1.0% during the 3rd quarter. Bridges Investment Management Inc. now owns 276,861 shares of the company’s stock worth $54,093,000 after buying an additional 2,780 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $176.82 on Friday. The firm has a market cap of $79.77 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 2.71 and a beta of 0.90. The company has a quick ratio of 2.09, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company’s fifty day simple moving average is $188.15 and its 200 day simple moving average is $179.35.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the firm posted $1.36 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. On average, analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 32.33%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ZTS shares. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.